You are here: Industry Insights > rGBM

News List

China NMPA Approves Phase III Clinical Trial of ASC40 Combined with Bevacizumab for Treatment of Patients with Recurrent Glioblastoma prnasia
July 22, 2021
Ascletis Pharma Inc. today announces that China National Medical Products Administration (NMPA) has approved the Phase III clinical trial application of ASC40 combined with Bevacizumab for treatment of patients with recurrent glioblastoma.
Clinical Trial Application of ASC40 Combined with Bevacizumab to Treat Patients with Recurrent Glioblastoma Accepted by China NMPA prnasia
May 25, 2021
Ascletis Pharma Inc. today announces that following the consultation with China National Medical Products Administration (NMPA), the clinical trial application of ASC40 combined with bevacizumab to treat patients with recurrent glioblastoma (rGBM) has ...
VBL Announces Patient Dosing of Recurrent Glioblastoma Multiforme Trial americanpharmaceuticalreview
March 04, 2021
VBL Therapeutics announced patient dosing has been initiated in a Phase 2 clinical trial investigating ofranergene obadenovec (VB-111) for the treatment of recurrent glioblastoma multiforme (rGBM).
PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020 prnasia
November 17, 2020
PharmAbcine Inc. announced that the company will present the final results of the Phase IIa clinical trial of Olinvacimab for rGBM (recurrent glioblastoma multiforme) patients at SNO (Society of Neuro-Oncology) 2020.